Indications
For adults:
– treatment of influenza and other acute respiratory infections;
– treatment of herpes infection.
Prevention of influenza and other acute respiratory infections in adults.
$25.00
Active ingredient: | |
---|---|
Dosage form: |
For adults:
– treatment of influenza and other acute respiratory infections;
– treatment of herpes infection.
Prevention of influenza and other acute respiratory infections in adults.
Hypersensitivity to tiloron or any other component of the drug;
– pregnancy and lactation;
– Children (under 18 years of age).
One film-coated tablet contains:
active substance: tilorone dihydrochloride – 125 mg;
auxiliary substances (core): cellulose microcrystalline – 105,0 mg; potato starch-46,0 mg; hypromellose (hydroxypropyl-methylcellulose)-4,0 mg hyprolose (hydroxyprop of tilcelulozei) -17,0 mg; magnesium stearate – 3.0 mg;
auxiliary substances (shell): OPA-dry II 85F220184 – 9.0 mg (macrogol (polyethylene glycol) 3350 – 2,7890 mg; talc – 1,1806 mg; titanium dioxide E 171 – 1,1874 mg; aluminum lacquer dye sunset yellow E 110 – of 1.3315 mg; dye iron oxide yellow E 172 – 1,1800 mg, dye Indigo Carmine E 132 — of 1.3315 mg).
One film-coated tablet contains: Active ingredient: tilorone dihydrochloride – 125 mg;excipients (core): microcrystalline cellulose – 105.0 mg; potato starch-46.0 mg; hypromellose (hydroxypropyl-methylcellulose)-4.0 mg, hyprolose (hydroxypropylcellulose) -17.0 mg; magnesium stearate-3.0 mg; excipients (shell): Opa – dry II 85F220184-9.0 mg (macrogol (polyethylene glycol) 3350 – 2.7890 mg; talc – 1.1806 mg; titanium dioxide E 171 – 1.1874 mg; aluminum varnish based on the dye sunny sunset yellow E 110 – 1.3315 mg; iron oxide yellow dye E 172 – 1.1800 mg, indigo carmine dye E 132 – 1.3315 mg).
Low molecular weight synthetic interferon inducer that stimulates the formation of all types of interferons (alpha, beta, gamma and lambda) in the body. The main producers of interferon in response to the introduction of tiloron are intestinal epithelial cells, hepatocytes, T-lymphocytes, neutrophils and granulocytes. After oral use, the maximum production of interferon is determined in the gut – liver – blood sequence after 4-24 hours. Tiloron has an immunomodulatory and antiviral effect. After a single oral use of tilorone at a dose equivalent to the maximum daily dose for humans, the maximum concentration in the lung tissue of interferon lambda was determined after 24 hours, interferon alpha-after 48 hours. Induction of interferon lambda in the lung tissue increases the antiviral protection of the respiratory tract in influenza and other respiratory viral infections. In human leukocytes, it induces the synthesis of interferon. It stimulates bone marrow stem cells, increases antibody formation depending on the dose, reduces the degree of immunosuppression, and restores the ratio of T-suppressors and T-helpers. It is effective against various viral infections, including influenza viruses, other acute respiratory viral infections, hepatitis viruses and herpesviruses. The mechanism of antiviral action is associated with the inhibition of translation of virus-specific proteins in infected cells, as a result of which viral reproduction is suppressed. Pharmacokineticsafter oral use, it is rapidly absorbed from the gastrointestinal tract. Bioavailability – 60%. About 80% of the drug binds to plasma proteins. The drug is excreted almost unchanged through the intestines (70%) and through the kidneys (9%). The elimination half-life (T 1/2) is 48 hours. The drug does not undergo biotransformation and does not accumulate in the body.
For adults: – treatment of influenza and other acute respiratory infections; – treatment of herpes infection. Prevention of influenza and other acute respiratory infections in adults.
The drug is contraindicated during pregnancy. If it is necessary to prescribe the drug during lactation, stop breastfeeding.
-Hypersensitivity to tilorone or any other component of the drug;- pregnancy and breast-feeding period; – children’s age (up to 18 years).
Possible allergic reactions, dyspeptic phenomena, short-term chills. If any of the side effects listed in the instructions get worse, or you notice any other side effects not listed in the instructions, tell your doctor.
It is compatible with antibiotics and drugs for the traditional treatment of viral and bacterial diseases. There was no clinically significant interaction of tilorone with antibiotics and traditional treatments for viral and bacterial diseases.
Tiloron is taken orally, after meals. For the treatment of influenza and other acute respiratory infections-125 mg per day for the first 2 days of treatment, then 125 mg after 48 hours. For the course-750 mg (6 tablets). For the prevention of influenza and other acute respiratory viral infections-125 mg 1 time a week for 6 weeks. For the course -750 mg (6 tablets). For the treatment of herpetic infection – the first two days of 125 mg, then after 48 hours of 125 mg. The course dose is 1.25-2.5 g (10-20 tablets). In the treatment of influenza and other acute respiratory viral infections, if symptoms persist for more than 4 days, you should consult a doctor.
Cases of overdose of the drug are unknown.
The effect of a medicinal product for medical use on the ability to drive vehicles, mechanisms and mechanisms does not adversely affect the ability to drive vehicles and engage in other potentially dangerous activities that require increased concentration of attention and speed of psychomotor reactions.
In a place protected from light, at a temperature not exceeding 25 °C. Keep out of reach of children.
life is 3 years.
Tiloron
Tablets
Reviews
There are no reviews yet